A Phase 1 Trial of MLN0128 in Combination With AZD9291 in Advanced EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor

Trial Profile

A Phase 1 Trial of MLN0128 in Combination With AZD9291 in Advanced EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Osimertinib (Primary) ; Sapanisertib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Oct 2016 Status changed from not yet recruiting to recruiting.
    • 13 Oct 2016 Planned primary completion date changed from 1 May 2017 to 1 Apr 2018.
    • 10 Oct 2016 Planned initiation date changed from 1 Oct 2015 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top